SOURCE: Lifeline Biotechnologies

Lifeline Biotechnologies

April 09, 2015 08:30 ET

Lifeline Biotechnologies (LLBO) Q1 2015 Update

RENO, NV--(Marketwired - Apr 9, 2015) - Management has filed the Company's Annual Report and Disclosure Statement for the year 2014 with OTC Markets. Current information, including financial statements and comprehensive information is included in the Disclosure Statement. Go to OTCMarkets, using Lifeline's stock symbol, LLBO (OTC PINK: LLBO) then search Filing and Disclosure tab.

Cyrcadia introduced its early breast tissue abnormality and early breast cancer detection technology products at the recent SxSW technology conference in Austin, Texas. The response has been overwhelming; currently there have been over 300,000 views of the Detected movie trailer. The Detected movie trailer can be viewed at The movie producers will be filming the clinical trials and incorporating it into the documentary.

Cyrcadia Health Is achieving meaningful added value as Cyrcadia prepares to enter the final clinical trials that will be conducted at El Camino Hospital (ECH) in Mountain View, CA and the Ohio State University (OSU) Oncology Hospital in Columbus, OH. The trials have been approved by the Investigational Review Board (IRB's) of ECH and are currently undergoing the review process at OSU. The trial is expected to be completed within four to 6 months. On completion Cyrcadia will obtain a CE Mark allowing for worldwide sales and marketing outside of the USA. On completion of the trials Cyrcadia will be submitting a 510(k) to the FDA. Post FDA clearance, marketing will begin in the USA. International sales are expected in Q4 of 2015 and US sales in Q1 or Q2 of 2016.

There is additional information on the LLBO page at IHub. The information has been posted by interested parties and not the Company. Accordingly, we cannot confirm the accuracy of all of the information.

About Lifeline Biotechnolgies, Inc. In 2008, Lifeline Biotechnologies created Cyrcadia, Inc. The main purpose of creating Cyrcadia was to establish a better value of its technology and to obtain financing at more favorable rates. LLBO's primary asset is its investment in Cyrcadia, Inc. and is its largest single shareholder. LLBO also has a five percent (5%) royalty based on all Cyrcadia product sales. Lifeline conducted three rounds of proof of concept trials, the results were validated by the Aero Space Engineers at Nangyany Technological University, Singapore. Nanyang's Aero Space Engineers are recognized world leaders in "Pattern Recognition," which is the basis of Lifeline's technology. Lifeline owns all of the issued software patents and has licensed them to Cyrcadia.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.

Contact Information